The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Why does the full potential of biosimilars remain untapped? Four experts weigh in.

We know that cell therapies work; now, we need to learn to manufacture them efficiently on an industrial scale.

Rare diseases aren’t the only field that can benefit from repurposing – the eye is also often overlooked.

Drug repurposing can benefit many areas of drug discovery – particularly rare diseases.

Collaboration is crucial for supply continuity and control.

Gene and Eva discuss the importance of being cautious when choosing a new supplier.

Pharmacy students take medicine safety lessons to school classrooms.

The latest business news and views in pharma.

What characteristics make a cancer therapy more likely to effectively treat disease?